LLY240927C1060000
- 0.02
- 0.000.00%
Eli Lilly and Co Newsroom
Eli Lilly and Co (LLY.US) Donanemab scores again: Japan approved, accelerating the expansion of the global Alzheimer's disease treatment market.
Eli Lilly and Co announced on Tuesday that its Alzheimer's drug donanemab has been approved by the Japan Ministry of Health, Labor and Welfare.
$1000 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today
Eli Lilly and Company (NYSE:LLY) Is Largely Controlled by Institutional Shareholders Who Own 88% of the Company
Roche Narrows Pipeline to 11 Disease Areas Amidst Weight Loss Push - WSJ
Novo CEO Faces Sen. Sanders in Drug Price Showdown -- Barrons.com
Novo Nordisk CEO Set to Defend Ozempic, Wegovy Prices on Capitol Hill
Eli Lilly and Co's Alzheimer's drug donanemab has been approved in Japan
On September 24th, Grorange reported that eli lilly and co announced on Tuesday that its Alzheimer's drug donanemab has been approved by the Japanese Ministry of Health, Labor and Welfare, providing a new treatment option for Japanese patients after the approval of Weiju and Bais. Japan is the second major market where donanemab has been approved, and the drug was previously marketed in the usa under the brand name Kisunla.
Eli Lilly's Alzheimer's Drug Approved in Japan
Express News | Eli Lilly: Kisunla Treatment for Early Onset Alzheimer's Disease Approved in Japan
Senate HELP Committee Hearing Could Get Heated as Novo Nordisk CEO Testifies
UCB Gets Expanded FDA Approval for Psoriasis Drug Bimzelx
Morgan Stanley Starts Structure Therapeutics at Overweight
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Spotlight on Eli Lilly: Analyzing the Surge in Options Activity
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,150
BofA Securities analyst Alec Stranahan maintains $Eli Lilly and Co(LLY.US)$ with a buy rating, and maintains the target price at $1,150.According to TipRanks data, the analyst has a success rate of 52
Mizuho Recommends Buying Corbus Following Its Drop Post-Novo's Obesity Data
Fed Uncertainty Is History. Now Markets Need to Brace for Election Volatility. -- Barrons.com
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Barclays analyst Carter Gould maintains $Eli Lilly and Co(LLY.US)$ with a buy rating, and maintains the target price at $1,025.According to TipRanks data, the analyst has a success rate of 55.6% and
Novo CEO Faces Sanders Over GLP-1 Drug Prices. All of Pharma Should Tune In. -- Barrons.com
Investing in This Healthcare Stock Could Be Like Catching Nvidia at the Dawn of the AI Boom